Comparative Pharmacology
Head-to-head clinical analysis: SCOPOLAMINE versus VESICARE LS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SCOPOLAMINE versus VESICARE LS.
SCOPOLAMINE vs VESICARE LS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Scopolamine is a competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3, M4, M5), blocking the action of acetylcholine at these receptors in the central nervous system and periphery.
Competitive antagonist at muscarinic acetylcholine receptors (M1–M5), with high selectivity for M3 receptors in the bladder detrusor muscle. Reduces involuntary bladder contractions and increases bladder capacity.
1.5 mg transdermal patch applied to postauricular skin every 72 hours; for prevention of motion sickness, apply 4-5 hours before exposure. Alternatively, 0.3-0.65 mg intramuscularly or intravenously every 6-8 hours as needed; or 0.4-0.8 mg subcutaneously. Oral dose: 0.4-0.8 mg every 6-8 hours as needed.
5 mg orally once daily; may increase to 10 mg once daily.
None Documented
None Documented
Clinical Note
moderateScopolamine + Venlafaxine
"The risk or severity of adverse effects can be increased when Scopolamine is combined with Venlafaxine."
Clinical Note
moderateScopolamine + Nefazodone
"The risk or severity of adverse effects can be increased when Scopolamine is combined with Nefazodone."
Clinical Note
moderateScopolamine + Stiripentol
"The risk or severity of adverse effects can be increased when Scopolamine is combined with Stiripentol."
Clinical Note
moderateScopolamine + Fesoterodine
Terminal elimination half-life is approximately 2–4 hours in adults; in elderly or hepatic impairment, half-life may be prolonged.
Terminal elimination half-life: 45 hours (range 32–68 h). Extended half-life allows once-daily dosing; steady-state reached in ~10 days.
Renal excretion of unchanged drug and metabolites accounts for approximately 50% of elimination; biliary/fecal excretion accounts for the remainder.
Renal: 68% (unchanged drug ~59%, metabolites ~9%), Fecal: 24% (metabolites), Biliary: negligible.
Category A/B
Category C
Anticholinergic
Anticholinergic
"The risk or severity of adverse effects can be increased when Scopolamine is combined with Fesoterodine."